These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

251 related items for PubMed ID: 21504133

  • 1. Evaluation of CSF biomarkers as predictors of Alzheimer's disease: a clinical follow-up study of 4.7 years.
    Hertze J, Minthon L, Zetterberg H, Vanmechelen E, Blennow K, Hansson O.
    J Alzheimers Dis; 2010; 21(4):1119-28. PubMed ID: 21504133
    [Abstract] [Full Text] [Related]

  • 2. Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia.
    Frölich L, Peters O, Lewczuk P, Gruber O, Teipel SJ, Gertz HJ, Jahn H, Jessen F, Kurz A, Luckhaus C, Hüll M, Pantel J, Reischies FM, Schröder J, Wagner M, Rienhoff O, Wolf S, Bauer C, Schuchhardt J, Heuser I, Rüther E, Henn F, Maier W, Wiltfang J, Kornhuber J.
    Alzheimers Res Ther; 2017 Oct 10; 9(1):84. PubMed ID: 29017593
    [Abstract] [Full Text] [Related]

  • 3. Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort.
    Seeburger JL, Holder DJ, Combrinck M, Joachim C, Laterza O, Tanen M, Dallob A, Chappell D, Snyder K, Flynn M, Simon A, Modur V, Potter WZ, Wilcock G, Savage MJ, Smith AD.
    J Alzheimers Dis; 2015 Oct 10; 44(2):525-39. PubMed ID: 25391385
    [Abstract] [Full Text] [Related]

  • 4. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment.
    Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, Herukka SK, van der Flier WM, Blankenstein MA, Ewers M, Rich K, Kaiser E, Verbeek M, Tsolaki M, Mulugeta E, Rosén E, Aarsland D, Visser PJ, Schröder J, Marcusson J, de Leon M, Hampel H, Scheltens P, Pirttilä T, Wallin A, Jönhagen ME, Minthon L, Winblad B, Blennow K.
    JAMA; 2009 Jul 22; 302(4):385-93. PubMed ID: 19622817
    [Abstract] [Full Text] [Related]

  • 5. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study.
    Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L.
    Lancet Neurol; 2006 Mar 22; 5(3):228-34. PubMed ID: 16488378
    [Abstract] [Full Text] [Related]

  • 6. Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia.
    Buchhave P, Minthon L, Zetterberg H, Wallin AK, Blennow K, Hansson O.
    Arch Gen Psychiatry; 2012 Jan 22; 69(1):98-106. PubMed ID: 22213792
    [Abstract] [Full Text] [Related]

  • 7. Addition of the Aβ42/40 ratio to the cerebrospinal fluid biomarker profile increases the predictive value for underlying Alzheimer's disease dementia in mild cognitive impairment.
    Baldeiras I, Santana I, Leitão MJ, Gens H, Pascoal R, Tábuas-Pereira M, Beato-Coelho J, Duro D, Almeida MR, Oliveira CR.
    Alzheimers Res Ther; 2018 Mar 20; 10(1):33. PubMed ID: 29558986
    [Abstract] [Full Text] [Related]

  • 8. Amyloid cascade and tau pathology cerebrospinal fluid markers in mild cognitive impairment with regards to Alzheimer's disease cerebral metabolic signature.
    Alexopoulos P, Guo LH, Jiang M, Bujo H, Grimmer T, Förster S, Drzezga A, Kurz A, Perneczky R.
    J Alzheimers Dis; 2013 Mar 20; 36(2):401-8. PubMed ID: 23609762
    [Abstract] [Full Text] [Related]

  • 9. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
    Lautner R, Palmqvist S, Mattsson N, Andreasson U, Wallin A, Pålsson E, Jakobsson J, Herukka SK, Owenius R, Olsson B, Hampel H, Rujescu D, Ewers M, Landén M, Minthon L, Blennow K, Zetterberg H, Hansson O, Alzheimer’s Disease Neuroimaging Initiative.
    JAMA Psychiatry; 2014 Oct 20; 71(10):1183-91. PubMed ID: 25162367
    [Abstract] [Full Text] [Related]

  • 10. Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice.
    Andreasen N, Minthon L, Davidsson P, Vanmechelen E, Vanderstichele H, Winblad B, Blennow K.
    Arch Neurol; 2001 Mar 20; 58(3):373-9. PubMed ID: 11255440
    [Abstract] [Full Text] [Related]

  • 11. Decreasing body mass index is associated with cerebrospinal fluid markers of Alzheimer's pathology in MCI and mild dementia.
    Mathys J, Gholamrezaee M, Henry H, von Gunten A, Popp J.
    Exp Gerontol; 2017 Dec 15; 100():45-53. PubMed ID: 29054536
    [Abstract] [Full Text] [Related]

  • 12. Cognitive impairment in late-life bipolar disorder is not associated with Alzheimer's disease pathological signature in the cerebrospinal fluid.
    Forlenza OV, Aprahamian I, Radanovic M, Talib LL, Camargo MZ, Stella F, Machado-Vieira R, Gattaz WF.
    Bipolar Disord; 2016 Feb 15; 18(1):63-70. PubMed ID: 26876913
    [Abstract] [Full Text] [Related]

  • 13. Performance of aβ1-40, aβ1-42, total tau, and phosphorylated tau as predictors of dementia in a cohort of patients with mild cognitive impairment.
    Parnetti L, Chiasserini D, Eusebi P, Giannandrea D, Bellomo G, De Carlo C, Padiglioni C, Mastrocola S, Lisetti V, Calabresi P.
    J Alzheimers Dis; 2012 Feb 15; 29(1):229-38. PubMed ID: 22232006
    [Abstract] [Full Text] [Related]

  • 14. Combining Cerebrospinal Fluid Biomarkers and Neuropsychological Assessment: A Simple and Cost-Effective Algorithm to Predict the Progression from Mild Cognitive Impairment to Alzheimer's Disease Dementia.
    Mazzeo S, Santangelo R, Bernasconi MP, Cecchetti G, Fiorino A, Pinto P, Passerini G, Falautano M, Comi G, Magnani G.
    J Alzheimers Dis; 2016 Oct 18; 54(4):1495-1508. PubMed ID: 27589522
    [Abstract] [Full Text] [Related]

  • 15. Erlangen Score as a tool to predict progression from mild cognitive impairment to dementia in Alzheimer's disease.
    Baldeiras I, Santana I, Leitão MJ, Vieira D, Duro D, Mroczko B, Kornhuber J, Lewczuk P.
    Alzheimers Res Ther; 2019 Jan 05; 11(1):2. PubMed ID: 30611311
    [Abstract] [Full Text] [Related]

  • 16. Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment.
    Hampel H, Teipel SJ, Fuchsberger T, Andreasen N, Wiltfang J, Otto M, Shen Y, Dodel R, Du Y, Farlow M, Möller HJ, Blennow K, Buerger K.
    Mol Psychiatry; 2004 Jul 05; 9(7):705-10. PubMed ID: 14699432
    [Abstract] [Full Text] [Related]

  • 17. Cerebrospinal fluid tau and beta-amyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment.
    Riemenschneider M, Lautenschlager N, Wagenpfeil S, Diehl J, Drzezga A, Kurz A.
    Arch Neurol; 2002 Nov 05; 59(11):1729-34. PubMed ID: 12433260
    [Abstract] [Full Text] [Related]

  • 18. Rapid progression from mild cognitive impairment to Alzheimer's disease in subjects with elevated levels of tau in cerebrospinal fluid and the APOE epsilon4/epsilon4 genotype.
    Blom ES, Giedraitis V, Zetterberg H, Fukumoto H, Blennow K, Hyman BT, Irizarry MC, Wahlund LO, Lannfelt L, Ingelsson M.
    Dement Geriatr Cogn Disord; 2009 Nov 05; 27(5):458-64. PubMed ID: 19420940
    [Abstract] [Full Text] [Related]

  • 19. Cerebrospinal fluid tau and Abeta42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment.
    Andreasen N, Minthon L, Vanmechelen E, Vanderstichele H, Davidsson P, Winblad B, Blennow K.
    Neurosci Lett; 1999 Sep 24; 273(1):5-8. PubMed ID: 10505638
    [Abstract] [Full Text] [Related]

  • 20. Cerebrospinal fluid biomarkers for Alzheimer’s disease: diagnostic performance in a homogeneous mono-center population.
    Johansson P, Mattsson N, Hansson O, Wallin A, Johansson JO, Andreasson U, Zetterberg H, Blennow K, Svensson J.
    J Alzheimers Dis; 2011 Sep 24; 24(3):537-46. PubMed ID: 21297262
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.